Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference. The post Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt…

Read More

Some Rural Hospitals Ditch Medicare Advantage

Rural hospital leaders are questioning whether they can continue to afford to do business with Medicare Advantage companies, and some say the only way to maintain services and protect patients is to end their contracts with the private insurers.  Medicare is the main federal health insurance program for people 65 or older. Participants can enroll…

Read More

California Continues Progressive Policies, With Restraint, in Divisive Election Year

SACRAMENTO, Calif. — This year, Gov. Gavin Newsom affirmed abortion access, calling California “a proud reproductive freedom state” and criticizing Republicans across the country for trying to take away families’ rights. He signed legislation mandating that insurance companies cover in vitro fertilization. He supported restricting students’ cellphone use in schools and signed a nation-leading ban…

Read More